LTR Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. The firm is developing and commercializing therapies that address significant unmet medical needs. The firm is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The firm is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The firm's subsidiary is LTR Pharma Inc.
Follow-Up Questions
LTPLF 주식의 가격 성능은 어떻습니까?
LTPLF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
LTR Pharma Ltd의 주요 사업 주제나 업종은 무엇입니까?
LTR Pharma Ltd은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
